NY:A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19. The data, which was published in Nature, show the vaccine created an immune response as demonstrated by "neutralising antibodies".
The Philippines plans to buy 40 million doses worth $400 million for 20 million people, around a fifth of the country's 107 million population, the country's Finance Secretary Carlos Dominguez said.More news: Fauci, White House COVID-19 task force officials testify on Capitol Hill
The head of the Russian Direct Investment Fund, Kirill Dmitriev, has likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite.
"A single-shot immunization has practical and logistical advantages over a two-shot regimen for global deployment and pandemic control, but a two-shot vaccine will likely be more immunogenic, and thus both regimens are being evaluated in clinical trials", Barouch added. All 20 animals that received the placebo developed high levels of virus in their lungs and nasal swabs.
The study saw the monkeys given a panel of vaccine prototypes before being exposed to SARS-CoV-2 infection.More news: One-Time US Republican Presidential Candidate Herman Cain Dies From COVID
In the best-performing candidate, which J&J selected for human testing, none of the animals had virus in their lungs and only one showed low levels of virus in nasal swabs.
Russia's Gamalei Institute is a reputable research centre which has developed clinically approved vaccines against MERS and Ebola but it has faced criticism of the scientific community after its director revealed that he and other staff self-administered the vaccine way before the start of human trials.
Meanwhile, Sanofi and GlaxoSmithKline said the United States government will pay $2.1 billion to them for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing.More news: Taylor Swift changes Folklore album merchandise after copyright claims
The team also noted that the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in 30,000 participants in September.